FGF21 and metabolic syndrome: Furthermore, FGF-21 showed predictive capabilities for insulin resistance and dyslipidemia; serum concentrations ≥269 ng/mL were linked to an 8-fold heightened risk of insulin resistance, while levels of ≥275.7 ng/mL were connected to a 4.02-fold increased risk of dyslipidemia.